A cancer treatment based on synergy between anti-angiogenic and immune cell therapies
From MaRDI portal
Publication:305603
DOI10.1016/j.jtbi.2016.01.026zbMath1343.92246OpenAlexW2251635988WikidataQ40812122 ScholiaQ40812122MaRDI QIDQ305603
Publication date: 30 August 2016
Published in: Journal of Theoretical Biology (Search for Journal in Brave)
Full work available at URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467856
Related Items (8)
Metaheuristics and Pontryagin's minimum principle for optimal therapeutic protocols in cancer immunotherapy: a case study and methods comparison ⋮ A fractional-order delay differential model with optimal control for cancer treatment based on synergy between anti-angiogenic and immune cell therapies ⋮ MATHEMATICAL MODELING OF IN-VIVO TUMOR-IMMUNE INTERACTIONS FOR THE CANCER IMMUNOTHERAPY USING MATURED DENDRITIC CELLS ⋮ Modeling the effect of immunotherapies on human castration-resistant prostate cancer ⋮ A structural methodology for modeling immune-tumor interactions including pro- and anti-tumor factors for clinical applications ⋮ Optimal control of variable-order fractional model for delay cancer treatments ⋮ A mathematical model for cancer treatment based on combination of anti-angiogenic and immune cell therapies ⋮ Optimal control for cancer treatment mathematical model using Atangana-Baleanu-Caputo fractional derivative
Cites Work
- A mathematical model of tumor-immune evasion and siRNA treatment
- On immunotherapies and cancer vaccination protocols: a mathematical modelling approach
- A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy
- A mathematical model of tumor-immune interactions
- Interactions between the immune system and cancer: A brief review of non-spatial mathematical models
- A mathematical model for pancreatic cancer growth and treatments
This page was built for publication: A cancer treatment based on synergy between anti-angiogenic and immune cell therapies
